Telos Biotech and Made Scientific announced a strategic evaluation collaboration to assess TELOVANCE™, a telomerase-based telomere lengthening platform, across multiple cell therapy manufacturing workflows. The collaboration will evaluate the technology in CAR-T cells, NK cells, and CD34+ hematopoietic stem/progenitor cells, measuring its effects on cell expansion, viability, phenotype, and functional performance. The feasibility data generated through the partnership is expected to support the development of more durable and effective cell therapies while demonstrating TELOVANCE’s compatibility with commercial manufacturing processes.
